Comparing Tafamidis vs Vutrisiran
| Tafamidis | Vutrisiran |
|
|---|
| Tafamidis | Vutrisiran |
|
|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis, Hereditary Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Hereditary Amyloidosis, Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vutrisiran may also be used for purposes not listed in this medication guide. View more |
|
| More about Tafamidis | More about Vutrisiran | |
| Ratings & Reviews | ||
|
Tafamidis has an average rating of 7.7 out of 10 from a total of 15 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 0% reported a negative effect. |
Vutrisiran has an average rating of 5.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Tafamidis side effects |
View all Vutrisiran side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Vyndamax, Vyndaqel | Amvuttra | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
59 hours |
5.2 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 32 drugs are known to interact with Tafamidis:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
May 03, 2019 |
June 13, 2022 |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Vutrisiran
Vutrisiran (brand name Amvuttra) is used to treat nerve damage associated with hereditary ...
Acoramidis
Acoramidis is used for cardiomyopathy of transthyretin-mediated amyloidosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.